Recent share performance and business mix

Universal Health Services (UHS) has seen its stock fall 34% year to date and 23% over the past year, even as the company reports annual revenue of about US$17.8b and net income of roughly US$1.5b.

At a recent share price of US$145.17 and a market value near US$8.8b, the stock is trading against a business that earns most of its revenue from two core segments: Acute Care Hospital Services and Behavioral Health Care Services.

Acute Care Hospital Services contribute about US$10.2b in revenue, while Behavioral Health Care Services add roughly US$7.6b, with other activities accounting for a smaller share of the total.

Over the past month and past 3 months, the stock declined about 15% and 24% respectively, which sits against a 3 year total return of about 8% and a 5 year total return that is down roughly 7%.

The recent share price return shows clear downward pressure, with the stock down about 34% year to date and the 1 year total shareholder return also down about 23%, even as Universal Health Services continues to generate sizeable revenue from its acute and behavioral health operations.

If you are reassessing your healthcare exposure after UHS's recent share price weakness, it can help to widen the lens and scan a focused list of 39 healthcare AI stocks.

With UHS trading at about a 50% discount to analyst price targets and an intrinsic discount near 68%, the question is whether the recent slide has gone too far or if the market is correctly pricing future growth.

Most Popular Narrative: 35.3% Undervalued

Against a last close of $145.17, the most widely followed narrative pegs Universal Health Services' fair value at $224.48, framing the recent selloff against a higher estimated worth.

Universal Health Services (NYSE: UHS) sits at the intersection of two powerful forces reshaping the U.S. healthcare system: rising demand for behavioral health services and the increasing recognition that mental health infrastructure is essential, not optional. While much of the market focuses on technology-driven healthcare narratives, UHS continues to demonstrate that scale, clinical depth, and operational discipline remain decisive advantages in an environment defined by complexity and long-term demand.

The fair value view here rests on more than sentiment. It leans on earnings power, a measured revenue growth path, and margin assumptions tied to a large behavioral health footprint. Curious which of those inputs does the heavy lifting in the $224.48 figure, and how a single discount rate shapes that outcome.

Result: Fair Value of $224.48 (UNDERVALUED)

However, this depends on reimbursement stability and tight cost control. Any policy shifts or sustained margin pressure could quickly challenge that fair value story.

Next Steps

If this combination of pressure and opportunity feels finely balanced, you may wish to act while the data is fresh and assess it yourself with 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If UHS has you rethinking your healthcare exposure, do not stop there. Widen your search and line up a few fresh candidates before the next move.

• Spot potential bargains early by scanning screener containing 21 high quality undiscovered gems that pair solid fundamentals with limited market attention.
• Prioritize resilience by using the 61 resilient stocks with low risk scores to focus on companies with steadier risk profiles.
• Target quality and financial strength together through the solid balance sheet and fundamentals stocks screener (46 results) to see which stocks meet a higher bar for balance sheet health.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.